Excellence in Scientific Discovery

The Institute's comprehensive investigations extend from the earliest phase of basic discovery to the development of new cancer diagnostics, treatment protocols and prevention strategies

Research Programs

Basic, clinical and translational studies into the biology of cancer and the factors that contribute to its onset and growth.


Shared Resources

The most sophisticated technologies and research protocols are offered to SCI members through a number of core facilities.


Key Initiatives

Inter-disciplinary teams of collaborative investigators partner to foster discovery, application and translation of scientific knowledge.


Institute Membership

Scientists and physicians from a wide range of disciplines, all dedicated to reducing the burden of cancer.


News & Publications

Publications, press releases and news are shared with scientists, physicians, patients and friends of the Institute.


Funding Opportunities

Internal and external sources of support for both established cancer research programs and promising new ideas.  


Clinical Trial Support

The Cancer Clinical Trials Office provides regulatory and administrative services to SCI members conducting clinical trials.  


Training Opportunities

Education and professional development designed to train the next generation of cancer researchers and physicians.



National Cancer Institute Designation

News & Publications

  • Next generation of CAR-T cells possible

    CAR-T cells are remarkably effective against blood cancers, but their effect can be transient as the cells become exhausted. Stanford researchers found a way to keep the cells effective in mice with human tumors.


  • Protein decoy stymies lung cancer in mice

    Researchers at Stanford and UCSF slowed the spread of a type of nonsmall cell lung cancer in mice by neutralizing a single protein that would otherwise set off a chain reaction, causing runaway tumor growth.


  • Identifying who benefits from chemo drug

    Anthracyclines can be effective against breast cancer but often have toxic side effects. Stanford researchers used gene expression levels to identify women most likely to benefit from the drugs, regardless of breast cancer type or stage.